<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of kidney irAEs in patients treated with immune checkpoint inhibitors*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of kidney irAEs in patients treated with immune checkpoint inhibitors*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Management of kidney irAEs in patients treated with immune checkpoint inhibitors*</div><div class="cntnt"><table cellspacing="0"><colgroup width="35%"></colgroup><colgroup width="65%"></colgroup> <tbody> <tr> <td class="subtitle1_single" colspan="2">6. Kidney toxicities</td> </tr> <tr> <td class="indent1" colspan="2">Nephritis and kidney dysfunction – diagnosis and monitoring: <ul class="decimal_heading"> <li>Clinical presentation and diagnosis.</li> <li>Definite ICPi-related nephritis or AKI: <ul> <li>Kidney biopsy-confirmed diagnosis compatible with ICPi nephritis or AKI, and after clinical review of risk factors.<sup>¶</sup></li> </ul> </li> <li>Probable ICPi-related nephritis or acute kidney failure: <ul> <li><strong>Both</strong> of the following: <ul> <li>Sustained increase in serum creatinine ≥50% on at least two consecutive values or need for RRT, after clinical review of risk factors.<sup>¶</sup></li> <li>Absence of an alternative plausible etiology.</li> </ul> </li> <li><strong>And</strong> at least one of the following: <ul> <li>Sterile pyuria (≥5 WBCs/hpf).</li> <li>Concomitant or recent extrarenal irAE-eosinophilia (≥500 cells per microliter).</li> </ul> </li> </ul> </li> <li>Possible ICPi-related nephritis or acute kidney failure: <ul> <li><strong>Both</strong> of the following: <ul> <li>Increase in serum creatinine ≥50%.</li> <li>Need for RRT nephritis or AKI is not readily attributable to alternative causes.</li> </ul> </li> </ul> </li> </ul> Monitoring: <ul class="decimal_heading"> <li>Monitor patients for elevated serum creatinine before every dose.</li> <li>Routine urinalysis is not necessary, other than to rule out UTIs etc.</li> <li>For any suspected immune-mediated adverse reactions, exclude other causes (refer to below).</li> <li>For suspected kidney irAE obtain urinalysis, consider referral to nephrology.</li> <li>For patients receiving combination therapy with ICPis and other agents, assess the potential contribution of the non-iCPI treatment to the kidney failure.</li> <li>Assess for concomitant medications, prescribed and OTC, herbals, vitamins, nephrotoxic agents, or contrast media.</li> <li>If no potential alternative cause of AKI is identified, then one can assume it is ICPi-related and should forego biopsy.</li> <li>Swift treatment of autoimmune component is important.</li> </ul> </td> </tr> <tr> <td class="subtitle1_single" colspan="2">6.1. Nephritis or AKI</td> </tr> <tr> <td class="subtitle2">Grading</td> <td class="subtitle2">Management</td> </tr> <tr> <td class="indent1">G1: Creatinine level increase of &gt;0.3 mg/dL; creatinine 1.5 to 2.0 times above baseline.</td> <td> <ul> <li>Consider temporarily holding ICPi and/or other potential contributing agents in combination regimens, pending consideration of potential alternative etiologies (recent IV contrast, medications, fluid status, and UTI) and baseline kidney function. A change that is still &lt;1.5 ULN could be meaningful.</li> </ul> </td> </tr> <tr> <td class="indent1">G2: Creatinine 2 to 3 times above baseline.</td> <td> <ul> <li>Hold ICPi temporarily.</li> <li>Consult nephrology.</li> <li>Evaluate for other causes (recent IV contrast, medications, and fluid status). If other etiologies are ruled out, administer 0.5 to 1 mg/kg/day prednisone equivalents.</li> <li>If worsening or no improvement after 1 week, increase to 1 to 2 mg/kg/day prednisone equivalents and permanently discontinue ICPi.</li> <li>If improved to ≤G1, taper steroids over at least 4 weeks.</li> <li>If no recurrence of CRI discuss resumption of ICPi with patient after taking into account the risks and benefits. Resumption of ICPi can be considered once steroids have been successfully tapered to ≤10 mg/day or discontinued.</li> </ul> </td> </tr> <tr> <td class="indent1">G3: Creatinine &gt;3 times baseline or &gt;4.0 mg/dL; hospitalization indicated.<hr/> G4: Life-threatening consequences; dialysis indicated; creatinine 6 times above baseline.</td> <td> <ul> <li>Permanently discontinue ICPi if ICPi is directly implicated in kidney toxicity.</li> <li>Consult nephrology.</li> <li>Evaluate for other causes (recent IV contrast, medications, fluid status, and UTI).</li> <li>Administer corticosteroids (initial dose of 1 to 2 mg/kg/day prednisone or equivalent).</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="2">Additional considerations: <ul class="decimal_heading"> <li>Monitor creatinine weekly.</li> <li>Reflex kidney biopsy should be discouraged until steroid treatment has been attempted.</li> </ul> </td> </tr> <tr> <td class="subtitle1_single" colspan="2">6.2. Nephritis or AKI – follow-up</td> </tr> <tr> <td class="subtitle2">Grading</td> <td class="subtitle2">Management</td> </tr> <tr> <td class="indent1">G1: Creatinine level increase of &gt;0.3 mg/dL; creatinine 1.5 to 2.0 times above baseline.</td> <td> <ul> <li>If improved to baseline: <ul> <li>Resume routine creatinine monitoring.</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">G2: Creatinine 2 to 3 times above baseline.</td> <td> <ul> <li>If improved to grade 1: <ul> <li>Taper corticosteroids over at least 4 weeks before resuming treatment with routine creatinine monitoring.</li> </ul> </li> <li>If elevations persist &gt;7 days or worsen and no other cause found, treat as grade 3.</li> </ul> </td> </tr> <tr> <td class="indent1">G3: Creatinine &gt;3 times baseline or &gt;4.0 mg/dL; hospitalization indicated.</td> <td> <ul> <li>If improved to grade 1: <ul> <li>Taper corticosteroids over at least 4 weeks.</li> </ul> </li> <li>If elevations persist &gt;3 to 5 days or worsen, consider additional immunosuppression (eg, infliximab, azathioprine, cyclophosphamide [monthly], cyclosporine, and mycophenolate).</li> </ul> </td> </tr> <tr> <td class="indent1">G4: Life-threatening consequences; dialysis indicated; creatinine 6 times above baseline.</td> <td> <ul> <li>If improved to grade 1: <ul> <li>Taper corticosteroids over at least 4 weeks.</li> </ul> </li> <li>If elevations persist &gt;2 to 3 days or worsen, consider additional immunosuppression (eg, infliximab, azathioprine, cyclophosphamide [monthly], cyclosporine, and mycophenolate).</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">ICPi: immune checkpoint inhibitor; 
	AKI: acute kidney injury; 
	RRT: renal replacement therapy; 
	WBC: white blood cells; 
	irAE: immune-related adverse event; 
	UTI: urinary tract infection; 
	OCT: over the counter; 
	ULN: upper limit of normal; 
	CRI: chronic renal insufficiency; 
	IV: intravenous.<br/>
	
	* The American Society of Clinical Oncology (ASCO) guidelines are intended to provide initial guidance in the management of treatment-related side effects. Consultation with appropriate specialists may be indicated.<br/>
	
	¶ Risk factors include prior or concomitant nephrotoxic agent(s) use and prior or concomitant extrarenal irAEs.</div><div class="graphic_reference">From: Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021; 39:4073. DOI: <a href="https://ascopubs.org/doi/full/10.1200/JCO.21.01440" target="_blank">10.1200/JCO.21.01440</a>. Copyright © 2022 American Society of Clinical Oncology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.</div><div id="graphicVersion">Graphic 116833 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
